Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | RBP4 | P02753 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3327214 | 0.79 | GAA (0.53) | GAAHRH3HSD11B1RBP4TRPV1 | |
| SCHEMBL3225833 | 0.76 | HSD11B1 (0.64) | GAAHSD11B1RBP4TRPV1ALDH1A1 | |
| SCHEMBL3205461 | 0.75 | GRM5 (0.61) | GAAHSD11B1RBP4TRPV1ALDH1A1 | |
| SCHEMBL3205429 | 0.75 | GAA (0.64) | GAAHRH3HSD11B1RBP4TRPV1 | |
| SCHEMBL22926473 | 0.74 | EPHX2 (0.62) | GAAHSD11B1RBP4TRPV1 | |
| SCHEMBL3095680 | 0.73 | HSD11B1 (0.76) | GAAHSD11B1RBP4TRPV1 | |
| SCHEMBL23515119 | 0.72 | EPHX2 (0.57) | GAAHRH3HSD11B1RBP4TRPV1 | |
| SCHEMBL6988200 | 0.72 | HSD11B1 (0.70) | GAAHSD11B1RBP4TRPV1NPSR1 | |
| SCHEMBL3222359 | 0.71 | HSD11B1 (0.62) | GAAHRH3HSD11B1RBP4TRPV1 | |
| SCHEMBL3219575 | 0.70 | GAA (0.60) | GAAHRH3HSD11B1RBP4TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | XIANG JASON SHAOYUN | 2010-02-04 | — | — | US | disclosed |
| US-7632838-B2 | 11-beta HSD1 inhibitors | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| CN-101400653-A | 11-beta HSD1 inhibitors | WYETH CORP (US) | 2009-04-01 | — | — | CN | disclosed |
| EP-1981848-A2 | 11-BETA HSD1 INHIBITORS | Wyeth (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
| WO-2007092435-A2 | 11-BETA HSD1 INHIBITORS | WYETH (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | HSD11B1, HSD3B1, HSD11B2 | GAA 2353/4885HRH3 3287/4885HSD11B1 1/4885 |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | HSD11B1, HSD11B2, HSD3B1 | GAA 2688/4885HRH3 2511/4885HSD11B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.